Prxcision
Infectious Disease Therapeutics · Health Care
Overview
Antibiotics once saved us—now it’s our turn. pRxcision® is the first AI-powered infectious disease platform delivering real-time decision support to ensure the right drug, dose, and timing—every time. Join the movement to stop antimicrobial resistance.
Funding and backers
Total raised
$3.1M
1 round on record
Latest round
$3.1M
Venture round · Jan 2023 · 3 yr ago
Team
11-50
employees, estimated range
The money's age
Long since its last round
45 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2023 | $3.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | PRXCISION, INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael GilbertExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
T cell Based Immunotherapies for Cancer and Chronic Infectious Diseases.
Our Mission and Innovation We are a biotechnology pioneer dedicated to solving one of the greatest challenges in modern medicine: the…
Paratek Pharmaceuticals is committed to developing and delivering innovative treatments for serious infectious diseases. Learn about our…
Smartbax is dedicated to developing innovative antibiotics to combat the rising threat of multi-drug-resistant bacteria and protect global…
Procarta Biosystems Ltd aims to revolutionise the treatment of serious and life-threatening infection through the development of innovative…
SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and…
Financials
Total raised
$3.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2023 | $3.1M | Details |
People
Michael Gilbert
Executive Officer
Paul Ambrose
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Schenectady
United States
HQ
10-50 est. staff